The Impact of Vagus Nerve Stimulation on Patients

What Vagus Nerve Stimulation Actually Does to the Body

Vagus nerve stimulation (VNS) delivers controlled electrical pulses to the vagus nerve to modulate brain and organ function. What began as a treatment for drug-resistant epilepsy in 1997 has expanded into one of the most actively investigated therapies in neuroscience, with FDA-approved applications now spanning epilepsy, depression, stroke rehabilitation, and cluster headache, and clinical trials underway for conditions ranging from rheumatoid arthritis to heart failure.

This article covers what VNS does at a physiological level, the current FDA-approved devices, emerging non-invasive options, and the evidence for each approved indication.

How VNS Works: The Mechanism

The vagus nerve carries approximately 80% afferent (sensory) fibers running from the body to the brain and 20% efferent (motor) fibers running from the brain to the organs. Most VNS therapeutic effects work through the afferent pathway: electrical stimulation activates sensory fibers that project to the nucleus tractus solitarius (NTS) in the brainstem, which then relays signals to widespread brain regions including the locus coeruleus, raphe nuclei, thalamus, and cortex.

This activation produces several measurable effects:

Neurotransmitter modulation — VNS increases norepinephrine release from the locus coeruleus and serotonin from the raphe nuclei, both of which are implicated in mood regulation and seizure suppression.
Anti-inflammatory signaling — Through the cholinergic anti-inflammatory pathway, VNS triggers acetylcholine release that acts on alpha-7 nicotinic receptors on immune cells, suppressing pro-inflammatory cytokines (TNF-alpha, IL-1-beta, IL-6).
Neuroplasticity enhancement — Precisely timed VNS paired with specific movements or sensory inputs strengthens synaptic connections, forming the basis of paired VNS therapy for stroke rehabilitation.
Autonomic rebalancing — VNS shifts the autonomic nervous system toward parasympathetic dominance, reducing heart rate, lowering blood pressure, and improving heart rate variability.

Your local vagus nerve experts

Find a vagus nerve practitioner near you

Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.

Or browse by approach

The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.

FDA-Approved VNS Devices and Indications

Implanted VNS (Invasive)

The original VNS system (LivaNova, formerly Cyberonics) involves surgically implanting a pulse generator beneath the skin of the left chest wall, connected by a lead wire wrapped around the left cervical vagus nerve. The device delivers intermittent electrical pulses according to programmed parameters (typically 30 seconds on, 5 minutes off). Patients also carry a handheld magnet that can trigger additional stimulation during seizure auras or depressive episodes.

Current FDA-approved indications for implanted VNS include:

Drug-resistant epilepsy (approved 1997) — For patients 4 years and older who have not responded adequately to anti-seizure medications. Registry data show approximately 50-60% of patients achieve at least a 50% reduction in seizure frequency after 2-3 years, with efficacy continuing to improve over time.
Treatment-resistant depression (approved 2005) — For adults who have failed at least 4 adequate antidepressant trials. Response rates in long-term studies (12+ months) reach approximately 30-40%, compared to 10-15% with treatment as usual. Notably, VNS for depression shows a delayed response pattern, with most improvement occurring between months 3 and 12.

Non-Invasive VNS (External Devices)

Two non-invasive approaches have received FDA clearance:

gammaCore (electroCore) — A handheld device applied to the neck over the cervical vagus nerve. It delivers transcutaneous electrical stimulation through the skin without surgery. FDA-cleared for acute treatment of episodic cluster headache (2017) and migraine (2018), and for prevention of cluster headache. The PREVA trial demonstrated a statistically significant reduction in cluster headache attacks compared to standard of care alone.

Transcutaneous auricular VNS (taVNS) — Targets the auricular branch of the vagus nerve (ABVN) in the ear, specifically the cymba conchae region where vagal innervation is most dense. Multiple commercial devices are available, including Nemos (Cerbomed) which has CE marking in Europe. A 2024 JAMA Network Open randomized trial demonstrated significant improvement in insomnia severity with nightly taVNS over 4 weeks. Research continues into taVNS for depression, epilepsy, tinnitus, and inflammatory conditions.

Paired VNS for Stroke Rehabilitation

Vivistim (MicroTransponder) received FDA approval in 2021 for upper extremity motor rehabilitation following ischemic stroke. This system pairs brief VNS pulses with specific arm and hand movements during rehabilitation exercises. The VNS-REHAB pivotal trial showed that patients receiving paired VNS achieved clinically meaningful improvements in arm function compared to rehabilitation alone, with benefits sustained at one year follow-up. The pairing mechanism works by releasing norepinephrine and acetylcholine during the precise moment of motor practice, strengthening the neural pathways being trained.

Investigational Applications

Active clinical trials are exploring VNS for several additional conditions:

Rheumatoid arthritis — SetPoint Medical has developed a bioelectronic medicine device targeting the cholinergic anti-inflammatory pathway. Clinical data have shown reductions in disease activity scores in patients with treatment-resistant RA. The device received FDA Breakthrough Device designation.
Heart failure — The ANTHEM-HFrEF trial investigated autonomic regulation therapy using VNS in patients with heart failure with reduced ejection fraction, with early results suggesting improvements in cardiac function and exercise capacity.
PTSD and anxiety disorders — Both invasive and non-invasive VNS are being studied for post-traumatic stress disorder, with preliminary results suggesting reductions in hyperarousal symptoms.
Inflammatory bowel disease — Based on the cholinergic anti-inflammatory pathway, VNS is being investigated for Crohn’s disease and ulcerative colitis.
Atrial fibrillation — The TREAT-AF trial explored low-level tragus stimulation for AF suppression, with initial results showing reduced AF burden in the active stimulation group.

What Patients Experience

The experience of VNS varies by device type and indication:

Implanted VNS

Surgery takes approximately 1-2 hours under general anesthesia. Most patients go home the same day. The device is typically activated 2-4 weeks after implantation, with parameters gradually increased over subsequent visits. Common side effects include hoarseness or voice changes during stimulation (reported by 30-60% of patients), cough, throat tingling, and shortness of breath. These effects are usually mild and occur only during active stimulation cycles. Battery life is typically 5-10 years, after which the generator is replaced in a minor outpatient procedure.

Non-Invasive VNS

External devices require no surgery. The gammaCore is self-administered by pressing the device against the neck for 2-minute treatment cycles. Auricular devices are typically worn like an earpiece for 1-4 hours daily. Side effects are generally mild: skin irritation at the electrode site, tingling, and occasional headache. There is no voice alteration with auricular stimulation.

Limitations and Considerations

VNS is not a cure for any of its approved indications. For epilepsy, it reduces seizure frequency but rarely eliminates seizures entirely. For depression, response rates are meaningful but not universal, and improvement is gradual. Non-invasive devices require consistent daily use for ongoing benefit.

Insurance coverage for VNS varies significantly. Implanted VNS for epilepsy is generally covered by major insurers. Coverage for depression is more variable and may require extensive documentation of treatment resistance. Non-invasive devices may or may not be covered, and some patients pay out of pocket.

Patients considering VNS should discuss their specific condition, treatment history, and expectations with a neurologist or specialist experienced in neuromodulation therapy. VNS works best as part of a comprehensive treatment plan, not as a standalone intervention.

Vagus nerve stimulation represents one of the most exciting frontiers in neuroscience and medicine. To understand the full scope of the vagus nerve and how it influences every major system in your body, get the My Vagus Nerve & Me eBook.